In this video, Michael Schweizer, MD, discusses the background, findings, and takeaways of the study, “Bipolar androgen therapy (BAT) plus Olaparib in men with metastatic castration-resistant prostate cancer (mCRPC),” presented recently at the 2021 European Society for Medical Oncology Annual Meeting. Schweizer is an associate professor in the division of medical oncology at the University of Washington and an associate professor in the clinical research division at the Fred Hutchinson Cancer Research Center, Seattle, Washington
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.